HopeStage
Back to all studies
CompletedNCT02970305

Pimavanserin for Negative Symptoms of Schizophrenia: A Placebo-Controlled Trial

About this titleRead the official source — NCT02970305

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

Medication studyAges 18–55Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
Phoenix and 100 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 4, 2016
Recruitment status
Completed
Enrollment listed in the registry
403
Sponsor
ACADIA Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada, Bulgaria, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT02970305
Official title
Show the full official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix, United States · Rogers, United States · Bellflower, United States

79 more locations
  • Lemon Grove, United States
  • Norwalk, United States
  • San Diego, United States
  • Santa Ana, United States
  • Torrance, United States
  • Hialeah, United States
  • Lauderhill, United States
  • Miami, United States
  • Tampa, United States
  • Atlanta, United States
  • Decatur, United States
  • Marietta, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Wichita, United States
  • Ann Arbor, United States
  • Las Vegas, United States
  • Berlin, United States
  • Albuquerque, United States
  • Rochester, United States
  • Charlotte, United States
  • Durham, United States
  • Oklahoma City, United States
  • Downingtown, United States
  • Charleston, United States
  • Irving, United States
  • Richardson, United States
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Targovishte, Bulgaria
  • Tserova Koria, Bulgaria
  • Varna, Bulgaria
  • Penticton, Canada
  • Chatham, Canada
  • Montreal, Canada
  • Toronto, Canada
  • Hradec Králové, Czechia
  • Pilsen, Czechia
  • Prague, Czechia
  • Říčany, Czechia
  • Kalocsa, Hungary
  • Budapest, Hungary
  • Debrecen, Hungary
  • Gyula, Hungary
  • Pécs, Hungary
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Lublin, Poland
  • Pruszcz Gdański, Poland
  • Roshchino, Russia
  • Plekhanovo, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Smolensk, Russia
  • Stavropol, Russia
  • Yaroslavl, Russia
  • Yekaterinburg, Russia
  • Belgrade, Serbia
  • Kovin, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Barcelona, Spain
  • Madrid, Spain
  • Oviedo, Spain
  • Valladolid, Spain
  • Zamora, Spain
  • Dnipro, Ukraine
  • Hlevakha, Ukraine
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Oleksandrivka, Ukraine
  • Poltava, Ukraine
  • Smila, Ukraine
  • Vinnytsia, Ukraine
  • Czechia
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Did this study involve medication?

Yes. The study involved medication, including Pimavanserin and Placebo.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies